Axa boosted its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 23.2% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 116,862 shares of the specialty pharmaceutical company’s stock after acquiring an additional 22,007 shares during the period. Axa owned 0.19% of Jazz Pharmaceuticals worth $17,091,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of JAZZ. Janus Henderson Group PLC increased its position in Jazz Pharmaceuticals by 11,990.7% in the 2nd quarter. Janus Henderson Group PLC now owns 873,919 shares of the specialty pharmaceutical company’s stock valued at $135,894,000 after acquiring an additional 866,691 shares during the period. FMR LLC increased its position in Jazz Pharmaceuticals by 11.4% during the 2nd quarter. FMR LLC now owns 8,290,410 shares of the specialty pharmaceutical company’s stock worth $1,289,159,000 after purchasing an additional 849,348 shares during the period. JPMorgan Chase & Co. increased its position in Jazz Pharmaceuticals by 41.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,405,408 shares of the specialty pharmaceutical company’s stock worth $218,540,000 after purchasing an additional 410,031 shares during the period. Schroder Investment Management Group acquired a new position in Jazz Pharmaceuticals during the 3rd quarter worth approximately $52,571,000. Finally, American Century Companies Inc. increased its position in Jazz Pharmaceuticals by 133.2% during the 2nd quarter. American Century Companies Inc. now owns 549,900 shares of the specialty pharmaceutical company’s stock worth $85,509,000 after purchasing an additional 314,094 shares during the period. Hedge funds and other institutional investors own 91.30% of the company’s stock.

Several equities analysts have issued reports on JAZZ shares. UBS reiterated a “buy” rating and set a $172.00 target price (down previously from $175.00) on shares of Jazz Pharmaceuticals in a research report on Monday, September 25th. BMO Capital Markets reiterated a “buy” rating and set a $196.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, September 20th. J P Morgan Chase & Co reiterated a “buy” rating and set a $190.00 target price on shares of Jazz Pharmaceuticals in a research report on Monday, September 18th. Royal Bank of Canada reiterated a “buy” rating and set a $210.00 target price on shares of Jazz Pharmaceuticals in a research report on Friday, September 15th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $190.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, August 30th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and nineteen have given a buy rating to the company’s stock. Jazz Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $181.28.

Shares of Jazz Pharmaceuticals PLC (NASDAQ JAZZ) opened at $134.09 on Tuesday. The company has a market capitalization of $8,125.16, a P/E ratio of 17.01, a PEG ratio of 0.87 and a beta of 0.98. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.94 and a current ratio of 3.10. Jazz Pharmaceuticals PLC has a 52 week low of $105.39 and a 52 week high of $163.75.

In other news, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $150.00, for a total transaction of $150,000.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Patrick G. Enright sold 352 shares of the business’s stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $133.19, for a total value of $46,882.88. Following the sale, the director now directly owns 1,365 shares in the company, valued at approximately $181,804.35. The disclosure for this sale can be found here. Insiders have sold a total of 18,552 shares of company stock worth $2,549,643 in the last three months. Corporate insiders own 4.30% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://www.watchlistnews.com/axa-buys-22007-shares-of-jazz-pharmaceuticals-plc-jazz/1772196.html.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.